The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis

Completed

• Conditions: Inflammatory Lung Diseases; Hemoptysis

• Registration Number: NCT01171768
• Lead Sponsor: Samsung Medical Center

Brief Summary

Vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) are major mediators of angiogenesis and are induced by tissue inflammation and hypoxia. While elevated serum VEGF levels have been reported in inflammatory lung diseases, especially with hemoptysis, there was no study to evaluate the Ang-2 levels in lung inflammatory diseases according to the presence of hemoptysis, inflammatory biomarker and hypoxia.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-06
• Study First Submitted: 2010-07-16
• Study First Submitted QC: 2010-07-27
• Study First Posted: 2010-07-28
• Study Completion: 2010-12
• Status Verified: 2011-07
• Last Update Submitted: 2011-07-20
• Last Update Posted: 2011-07-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 52

Inclusion Criteria

• patients visited Samsung Medical Center for the treatment of benign inflammatory disease such as bronchiectasis, aspergilloma, pneumonia and post-tuberculosis destroyed lung

Exclusion Criteria

• patients with tumorous condition including lung cancer, vasculitis and the lung disease associated with collagen vascular disease on the point of enrollment

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
serum VEGF and Ang-2 level in lung inflammatory disease according to the presence of hemoptysis	up to 7 days after enrollment	We'll measure the serum VEFG and Ang-2 level of enrolled patients within a week from the moment that patients agree to enroll this study. Therefore, Comparison of the serum VEGF and Ang-2 level (measured within a week from enrollment) according to the presence of hemoptysis will be primary outcome.

Secondary Outcome Measures

Name	Time	Method
to investigate association between angiogenesis factors and other factors such as inflammatory biomarker and hypoxia.	up to 7 days after enrollment	We'll measure the serum VEFG, Ang-2 level, and other factors such as inflammatory biomarkers and PaO2 of enrolled patients within a week from the moment that patients agree to enroll this study. Therefore, Investigating association between angiogensis factors and other factors such as inflammatory biomarker and hypoxia, which were measured within a week from enrollment, will be secondary outcome.

Trial Locations

Locations (1)

Samsung Medical Center; 🇰🇷 Seoul, Korea, Republic of